FDA Brief

Warning letters Drugs

FDA warning letter to

Fallien Cosmeceuticals Ltd. dba Fallene Ltd.

MediumIssued Aug 6, 2025Posted Aug 12, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Fallien over unapproved OTC sunscreen foam TiZO SHEERFOAM SPF 30 sold without required authorization.

What happened

On May 14, 2025, FDA reviewed the company’s website and Instagram and Facebook pages, which direct consumers to the website to buy TiZO SHEERFOAM SPF 30. FDA treated the product as an OTC sunscreen drug because its labeling says it helps prevent sunburn. FDA found no approved application for the product and said the foam/mousse dosage form is not authorized for marketing under the OTC sunscreen order M020.

What FDA found

  1. The product is a drug because its labeling says it helps prevent sunburn and affects the body.

    FD&C Act §201(g)(1)(B)-(C), 21 U.S.C. 321(g)(1)(B)-(C)
  2. The OTC sunscreen is misbranded because it is marketed without an FDA-approved application and does not meet section 505G requirements.

    FD&C Act §502(ee), 21 U.S.C. 352(ee); §505G, 21 U.S.C. 355h
  3. The foam/mousse dosage form is not among the sunscreen dosage forms allowed under M020, and no final order authorizes foam sunscreens.

    FD&C Act §505G(m)(2), 21 U.S.C. 355h(m)(2); OTC Monograph M020
  4. Shipping the misbranded drug in interstate commerce violates the law.

    FD&C Act §301(a), 21 U.S.C. 331(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, prevent recurrence, and provide related documentation. If the company believes there is no violation, it must send its reasoning and supporting information.

Who should pay attention

  • other OTC sunscreen brands selling nonstandard dosage forms
  • contract manufacturers and marketers of foam or mousse sunscreens
  • retailers and distributors selling OTC sunscreen drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  2. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  3. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  4. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk